Seres Q2 net income $4.6M on $25M Nestlé milestone; cash runway through Q1 2027

Seres Therapeutics, Inc.

Net income of $4.6M vs net loss of $19.9M YoY; $25M gain from Nestlé milestone termination payment.
Cash and equivalents $15.6M at June 30; expects additional $12.5M from Nestlé in Oct 2026; funds operations through Q1 2027.
SER-155 in irEC: 80% (12/15) achieved immunosuppressive-free clinical response at day 15 in MSK IST.
Terminated 200 Sidney Street lease; further reduces annual facility cash costs from 2027.
Engaging partners for SER-155 (allo-HCT, irEC) and SER-603 (IBD); seeking capital to advance pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.